Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular
KEYWORDS: aspirin, clopidogrel, people, dipyridamole, treatment, modified-release dipyridamole, modified-release, stroke, compared, ischaemic, plus, plus aspirin, qaly, dipyridamole plus, disease

aspirin, unless contraindicated, and continued for 12 months. For people who have had an ST-segment-elevation myocardial infarction (STEMI), NICE's previous guideline on MI: secondary prevention (now replaced by NICE's guideline on acute coronary syndromes) recommended that patients treated with a combination of aspirin and clopidogrel during the first 24 hours after the myocardial infarction should continue this treatment for at least 4 weeks. Thereafter, standard treatment including low-dose aspirin should be given, unless there are other indications to continue dual antiplatelet therapy. 2.7 The 'National service framework for coronary heart disease' states that GPs and primary care trusts should identify all people with established cardiovascular disease and offer them comprehensive advice and appropriate treatment to reduce their risk of recurrent occlusive vascular events. GP contracts include points for the number of people with coronary heart disease or who have had a stroke and who are taking antiplatelet therapy for secondary prevention. 3 The technologies 3.1 Clopidogrel (Plavix, Sanofi-Aventis, Bristol-Myers Squibb) is an irreversible adenosine diphosphate-receptor antagonist with antiplatelet properties. Clopidogrel is available as branded and generic preparations and has a marketing authorisation for 'the prevention of atherothrombotic events in patients suffering from myocardial infarction (from a few days until less
